Around 18 percent of American adults suffer from anxiety, making it one of the most common mental health issues in the United States, according to the National Institute for Mental Health.
Comorbidity of syndromes is common, with 50% of adults with psychiatric disorders battling two or more disorders. The Psychiatric Times notes that comorbid anxiety and depression is found among at least 60% of adults with psychiatric syndromes.
As a result, comorbid anxiety and depression accounted for as much as 4 percent of all medical disability worldwide in 2007.
Alpha-Stim is FDA cleared to treat BOTH Anxiety and Depression.
A research report from the Journal of Affective Disorders in 2014 chronicled a clinical study of cranial electrotherapy stimulation for anxiety and comorbid depression, which found that the use of Alpha-Stim CES technology led to significant results.
“Anxiety disorders are among the most prevalent mental disorders and are usually treated with medication and/or psychotherapy. When anxiety disorders are accompanied with comorbid depression, this further complicates the treatment process,” the report noted. “Medication compliance is a common problem due to adverse side effects and new and effective treatments that have minimal side effects are needed for the treatment of anxiety and depression.”
The study, which used a randomized, double-blind, sham controlled design to examine the effectiveness of Alpha-Stim as a treatment for anxiety disorders and comorbid depression, tested 115 adult participants.
The group using the Alpha-Stim reported a 94% decrease in anxiety and a 75% decrease in depression over a 5-week period.
One of the most important conclusions that came from the clinical trial was that participants “reported no adverse effects” from use of the Alpha-Stim CES during the study.